Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
General drug-use survey for Corectim in atopic dermatitis
jRCT2031210295Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of budesonide in atopic dermatitis (AD), sponsored by Shionogi & Co., Ltd. Primary endpoints: Incidence of onset of skin infection and Incidence of onset of malignant tumor. Started Oct 2021; status: active, not recruiting.
02
Drugs
budesonide
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031210295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210295.